vs
Side-by-side financial comparison of AVIENT CORP (AVNT) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $760.6M, roughly 2.0× AVIENT CORP). BeOne Medicines Ltd. runs the higher net margin — 4.4% vs 2.2%, a 2.2% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 1.9%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $125.4M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs -4.2%).
Avient Corporation is a global materials solutions company headquartered in Avon Lake, Ohio, United States, employing approximately 9,000 people worldwide. Its products include colorants, advanced composites, functional additives and engineered materials.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
AVNT vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $760.6M | $1.5B |
| Net Profit | $16.9M | $66.5M |
| Gross Margin | 30.2% | 90.5% |
| Operating Margin | 5.2% | 12.4% |
| Net Margin | 2.2% | 4.4% |
| Revenue YoY | 1.9% | 32.8% |
| Net Profit YoY | -65.0% | 143.8% |
| EPS (diluted) | $0.18 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $760.6M | $1.5B | ||
| Q3 25 | $806.5M | $1.4B | ||
| Q2 25 | $866.5M | $1.3B | ||
| Q1 25 | $826.6M | $1.1B | ||
| Q4 24 | $746.5M | $1.1B | ||
| Q3 24 | $815.2M | $1.0B | ||
| Q2 24 | $849.7M | $929.2M | ||
| Q1 24 | $829.0M | $751.7M |
| Q4 25 | $16.9M | $66.5M | ||
| Q3 25 | $32.6M | $124.8M | ||
| Q2 25 | $52.6M | $94.3M | ||
| Q1 25 | $-20.2M | $1.3M | ||
| Q4 24 | $48.3M | $-151.9M | ||
| Q3 24 | $38.2M | $-121.3M | ||
| Q2 24 | $33.6M | $-120.4M | ||
| Q1 24 | $49.4M | $-251.2M |
| Q4 25 | 30.2% | 90.5% | ||
| Q3 25 | 30.4% | 86.1% | ||
| Q2 25 | 32.1% | 87.5% | ||
| Q1 25 | 31.8% | 85.2% | ||
| Q4 24 | 34.8% | 85.8% | ||
| Q3 24 | 32.1% | 83.0% | ||
| Q2 24 | 30.3% | 85.1% | ||
| Q1 24 | 33.6% | 83.4% |
| Q4 25 | 5.2% | 12.4% | ||
| Q3 25 | 8.3% | 11.5% | ||
| Q2 25 | 11.1% | 6.7% | ||
| Q1 25 | 0.1% | 1.0% | ||
| Q4 24 | 11.5% | -7.0% | ||
| Q3 24 | 9.5% | -12.0% | ||
| Q2 24 | 8.5% | -11.5% | ||
| Q1 24 | 11.3% | -34.8% |
| Q4 25 | 2.2% | 4.4% | ||
| Q3 25 | 4.0% | 8.8% | ||
| Q2 25 | 6.1% | 7.2% | ||
| Q1 25 | -2.4% | 0.1% | ||
| Q4 24 | 6.5% | -13.5% | ||
| Q3 24 | 4.7% | -12.1% | ||
| Q2 24 | 4.0% | -13.0% | ||
| Q1 24 | 6.0% | -33.4% |
| Q4 25 | $0.18 | $0.05 | ||
| Q3 25 | $0.36 | $0.08 | ||
| Q2 25 | $0.57 | $0.06 | ||
| Q1 25 | $-0.22 | $0.00 | ||
| Q4 24 | $0.53 | $-0.10 | ||
| Q3 24 | $0.41 | $-0.09 | ||
| Q2 24 | $0.36 | $-0.09 | ||
| Q1 24 | $0.54 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $4.5B |
| Total DebtLower is stronger | $1.9B | $836.4M |
| Stockholders' EquityBook value | $2.4B | $4.4B |
| Total Assets | $6.0B | $8.2B |
| Debt / EquityLower = less leverage | 0.81× | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.5B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.6B | ||
| Q1 24 | — | $2.8B |
| Q4 25 | $1.9B | $836.4M | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.1B | — |
| Q4 25 | $2.4B | $4.4B | ||
| Q3 25 | $2.4B | $4.1B | ||
| Q2 25 | $2.4B | $3.8B | ||
| Q1 25 | $2.3B | $3.5B | ||
| Q4 24 | $2.3B | $3.3B | ||
| Q3 24 | $2.4B | $3.4B | ||
| Q2 24 | $2.3B | $3.4B | ||
| Q1 24 | $2.3B | $3.4B |
| Q4 25 | $6.0B | $8.2B | ||
| Q3 25 | $6.1B | $7.6B | ||
| Q2 25 | $6.1B | $6.3B | ||
| Q1 25 | $5.8B | $5.8B | ||
| Q4 24 | $5.8B | $5.9B | ||
| Q3 24 | $6.0B | $5.8B | ||
| Q2 24 | $5.9B | $5.7B | ||
| Q1 24 | $5.9B | $5.7B |
| Q4 25 | 0.81× | 0.19× | ||
| Q3 25 | 0.83× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.90× | — | ||
| Q4 24 | 0.89× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 0.90× | — | ||
| Q1 24 | 0.90× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $167.8M | $417.3M |
| Free Cash FlowOCF − Capex | $125.4M | $379.8M |
| FCF MarginFCF / Revenue | 16.5% | 25.4% |
| Capex IntensityCapex / Revenue | 5.6% | 2.5% |
| Cash ConversionOCF / Net Profit | 9.93× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | $195.0M | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.8M | $417.3M | ||
| Q3 25 | $72.1M | $402.6M | ||
| Q2 25 | $112.8M | $263.6M | ||
| Q1 25 | $-51.1M | $44.1M | ||
| Q4 24 | $122.6M | $75.2M | ||
| Q3 24 | $71.1M | $188.4M | ||
| Q2 24 | $105.9M | $-95.6M | ||
| Q1 24 | $-42.8M | $-308.6M |
| Q4 25 | $125.4M | $379.8M | ||
| Q3 25 | $47.4M | $354.5M | ||
| Q2 25 | $85.8M | $219.8M | ||
| Q1 25 | $-63.6M | $-12.3M | ||
| Q4 24 | $81.5M | $-17.3M | ||
| Q3 24 | $46.1M | $54.7M | ||
| Q2 24 | $74.5M | $-205.5M | ||
| Q1 24 | $-67.2M | $-465.1M |
| Q4 25 | 16.5% | 25.4% | ||
| Q3 25 | 5.9% | 25.1% | ||
| Q2 25 | 9.9% | 16.7% | ||
| Q1 25 | -7.7% | -1.1% | ||
| Q4 24 | 10.9% | -1.5% | ||
| Q3 24 | 5.7% | 5.5% | ||
| Q2 24 | 8.8% | -22.1% | ||
| Q1 24 | -8.1% | -61.9% |
| Q4 25 | 5.6% | 2.5% | ||
| Q3 25 | 3.1% | 3.4% | ||
| Q2 25 | 3.1% | 3.3% | ||
| Q1 25 | 1.5% | 5.0% | ||
| Q4 24 | 5.5% | 8.2% | ||
| Q3 24 | 3.1% | 13.3% | ||
| Q2 24 | 3.7% | 11.8% | ||
| Q1 24 | 2.9% | 20.8% |
| Q4 25 | 9.93× | 6.28× | ||
| Q3 25 | 2.21× | 3.22× | ||
| Q2 25 | 2.14× | 2.79× | ||
| Q1 25 | — | 34.71× | ||
| Q4 24 | 2.54× | — | ||
| Q3 24 | 1.86× | — | ||
| Q2 24 | 3.15× | — | ||
| Q1 24 | -0.87× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNT
| Color Additives And Inks | $466.0M | 61% |
| Specialty Engineered Materials | $295.5M | 39% |
ONC
Segment breakdown not available.
